Shanghai Jmt-bio Inc.
Clinical trials sponsored by Shanghai Jmt-bio Inc., explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New drug JMT206 tested for safety in first human trial Results expected Sep 2026 (estimated)
- New hope for advanced cancer? JMT106 injection enters first human trial Results expected Nov 2026 (estimated)
- New shot JMT108 targets tough melanoma in early trial Results expected Nov 2026 (estimated)
- New two-drug combo aims to wipe out HER2 breast cancer before surgery Results expected Dec 2026 (estimated)
- New hope for HER2+ breast cancer: experimental drug JSKN003 faces off against standard therapy Results expected May 2027 (estimated)
-
New hope for HER2+ breast cancer: experimental drug JSKN003 faces off against standard therapy
Disease control Not yet recruitingThis phase 2 study tests whether a new drug called JSKN003 works better than the current standard therapy for people with HER2-positive breast cancer that has returned or spread. About 60 adults who have not had prior treatment for advanced disease will receive either JSKN003 or …
Phase 2 • Sponsor: Shanghai JMT-Bio Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New drug cocktail aims to tackle tough lung cancers
Disease control Not yet recruitingThis early-phase study tests a new drug called SYS6090 combined with standard chemotherapy or other drugs in about 600 people with advanced lung cancer (non-small cell or small cell). The goal is to see if the combinations are safe and if they can shrink tumors. The trial is not …
Phase 1/2 • Sponsor: Shanghai JMT-Bio Inc. • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
New hope for tough colorectal cancer: JSKN003 trial launches
Disease control Not yet recruitingThis Phase 3 trial tests a new drug called JSKN003 against standard treatments for people with advanced HER2-positive colorectal cancer that has not responded to three common chemotherapies. About 123 participants will be randomly assigned to receive either JSKN003 or a standard …
Phase 3 • Sponsor: Shanghai JMT-Bio Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
New hope for stomach cancer: drug cocktail targets tough tumors
Disease control Not yet recruitingThis study tests a new drug called KN026, combined with chemotherapy and an immunotherapy (enlonstobart), as a first treatment for people with HER2-positive advanced stomach cancer that cannot be removed by surgery. About 490 participants will be split into groups to compare this…
Phase 2/3 • Sponsor: Shanghai JMT-Bio Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC